- Regulatory Status
- RUO
- Other Names
- STK39, DCHT, PASK, SPAK, Serine/Threonine Kinase 39, ProlineAlanine-Rich STE20-Related Kinase, Small Intestine SPAK-LikeKinase, STE20/SPS1 Homolog, Ste20-Like Protein Kinase 3
Cat # | Size | Price | Quantity Check Availability | ||
---|---|---|---|---|---|
584206 | 100 µg | $300.00 |
Serine/threonine kinase 39 (STK39) is a member of the Ste20-like kinase family, composed of N-terminal series of proline and alanine repeats, a kinase catalytic domain and a C-terminal regulatory domain. STK39 is associated with Parkinson’s disease, hypertension, autism, and various types of cancer. Its expression levels have been linked to neuroprotection, particularly in Parkinson’s disease. Studies have demonstrated that STK39 rs6749447 is in linkage disequilibrium with the STK39 regulatory region variants rs1955337 and rs1474055, both of which are associated with Parkinson’s disease. STK39 expression is linked to tumor malignancy. It also plays crucial roles in migration, invasion, and proliferation of non-small cell type lung cancer cells. STK39 is involved in the cellular stress response pathway via activating p38 MAPK. In addition, it regulates the water/salt balance and blood pressure by phosphorylating the sodium chloride co-transporter. STK39 plays a key role in various cellular processes, including protein interaction, cell signaling, and biological functions. It is part of the with-no-lysine kinases signaling cascade, essential for maintaining cellular ion homeostasis. It interacts with and phosphorylates other proteins, including SNAI1.
Product Details
- Source
- Human STK39, amino acids (Met1-Ser545) (Accession #Q9UEW8-1) with a N-terminal 6His tag and C-terminal Avi tag was expressed in insect cells.
- Molecular Mass
- The 573 amino acid recombinant protein has a predicted molecular mass of approximately 63 kD. The DTT-reduced and non-reduced protein migrates at approximately 62-80 kD by SDS-PAGE. The N-terminal amino acid is Met.
- Purity
- > 85% as determined by Coomassie stained SDS-PAGE.
- Formulation
- Protein is formulated in 50 mM HEPES, 150 mM NaCl, 25% Glycerol, 1 mM TCEP, 0.1 mM PMSF, pH 7.5
- Concentration
- 100 µg at 0.5 mg/mL
- Storage & Handling
- Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
- Application
-
Standard
- Application Notes
-
BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are validated in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.
Antigen Details
- Structure
- Monomer
- Distribution
-
STK39 is highly expressed in the renal cell carcinomas and various tumor tissues
- Function
- STK39 is associated with Parkinson’s disease, hypertension, autism, and various types of cancer
- Interaction
- PLK1
- Cell Type
- Astrocytes, B cells, Endothelial cells, Fibroblasts, Granulocytes, Macrophages, Neurons, NK cells, Oligodendrocytes, T cells, Th17
- Biology Area
- Cell Biology, Immunology, Neurodegeneration, Neuroscience, Signal Transduction
- Molecular Family
- Enzymes and Regulators, Phospho-Proteins, Protein Kinases/Phosphatase
- Antigen References
-
- Johnston AM, et al. 2000. Oncogene. 19:4290-7.
- Zhang C, et al. 2021. Theranostics. 11:2108-2122.
- Qiu Z, et al. 2021. Theranostics. 11:7658-7670.
- Hao X, et al. 2021. iScience. 24:103223.
- Balatoni CE, et al. 2009. Am J Pathol. 175:1653-61.
- Zhao Li, et al. 2016. Oncotarget. 7:61366-61377.
- Chen Y, et al. 2018. J Mol Neurosci.64:574-580.
- Wang YQ, et al. 2014. Neurosci Lett. 30:566:206-9.
- Huang T, et al. 2017. Oncol Lett. 14:4599-4604.
- Li NN, et al. 2013. PLoS One. 8:e79211.
- Kunnas T, et al. 2021. Medicine. 100:e27566.
- Gene ID
- 27347 View all products for this Gene ID
- UniProt
- View information about STK39 on UniProt.org